Coronavirus Smell Therapy for Anosmia Recovery

NCT ID: NCT04422275

Last Updated: 2021-03-02

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2023-12-31

Brief Summary

As the COVID-19 pandemic spread around the world, anosmia and dysgeusia were quickly recognized as two of the key presenting symptoms. The probability of return of smell is related to severity of smell loss at presentation, but it appears that the loss of sense of smell and taste seems to persist in approximately 10% of the affected patients after 6 months. As a result of COVID-19, it is estimated that within the next 12 months > 150,000 Americans will suffer permanent loss of smell. The magnitude of this impairment on the health, safety, and quality of life is truly unprecedented and makes post-COVID olfactory disorder a major public health problem. Thus, there is a pressing need to identify effective treatments.

The research questions are to determine the effects of steroid nasal saline lavage and olfactory training among adults with post-COVID olfactory dysfunction and identify confounders and modifiers of any observed effects. To answer the research question, the investigators propose a 2 x 2 factorial design blinded randomized clinical trial whereby 220 subjects with documented COVID-19 with anosmia/hyposmia of 12 weeks duration or longer from Missouri, Illinois, and Indiana will be recruited electronically from COVID patient advocacy sites, social media sites, and other internet sources. Enrolled subjects will be randomized to nasal saline lavage with topical budesonide or placebo to address the presumed role of inflammation in the olfactory cleft and each subject will also be randomized to olfactory training with patient-specific, high- or low-concentration essential oil scent to assess the role of olfactory training. Data will be analyzed in a blinded fashion to allow estimation of observed effect size for both anti-inflammatory and olfactory training.

This innovative study will exploit the unique opportunities presented by COVID-19. The study will use a high-tech virtual "contactless" research strategy, including eConsent and digital mHealth techniques to obtain rapid answers to the research questions. The interventions are low-cost, readily available, and results of this study can be directly disseminated to the care of COVID-19 patients with anosmia.

Detailed Description

This will be a virtual or "contactless" clinical trial. Subjects will be recruited through a variety of ways and will complete all baseline and post-intervention assessments via specially designed electronic platforms, including REDCap and digital eHealth assessments. There will be no in-person, on-campus interaction between the members of the study team and research participants.

Convalescent COVID-19 subjects with persistent (i.e. > 3 months) decreased sense of smell, and a score on the UPSIT consistent with decreased olfactory function (< 35 women, < 34 men) will be offered enrollment. This will be a 2 x 2 factorial double-blinded, placebo-controlled, randomized clinical trial.

Subjects will be assigned to one of two nasal saline lavage interventions through a randomization schedule developed by the Study Pharmacist. The package and detailed instructions will be shipped directly to the subject from pharmacy. Subjects will be requested to rinse each nasal cavity once daily for 12 weeks and to keep track of their daily use through a paper dairy or specially created app to track compliance.

Subjects will be assigned to one of two olfactory training interventions through a randomization schedule prepared by the Study Pharmacist. The smell training intervention will be shipped directly to the subject. The subject will be expected to complete the smell training for 12 weeks as instructed. Subjects will be asked to record their daily training on a specially created app and make observations on their smell or taste function at the end of every week.

Outcome assessments will be performed immediately upon completing nasal saline lavage and olfactory training (Week 12) and follow-up (Week 24).

Conditions

Anosmia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Budesonide & High-Concentration OLF

In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.

Group Type: ACTIVE_COMPARATOR

Budesonide

Intervention Type: DRUG

The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.

High-Concentration Essential Oil

Intervention Type: BEHAVIORAL

High-concentration essential oil will include 1 ml of essential oil per jar.

Placebo & High-Concentration OLF

In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.

Group Type: ACTIVE_COMPARATOR

High-Concentration Essential Oil

Intervention Type: BEHAVIORAL

High-concentration essential oil will include 1 ml of essential oil per jar.

Placebo

Intervention Type: DRUG

The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.

Budesonide & Low-Concentration OLF

In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.

Group Type: ACTIVE_COMPARATOR

Budesonide

Intervention Type: DRUG

The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.

Low-Concentration Essential Oil

Intervention Type: BEHAVIORAL

Low-concentration essential oil will include 0.1 ml of essential oil per jar.

Placebo & Low-Concentration OLF

In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.

Low-Concentration Essential Oil

Intervention Type: BEHAVIORAL

Low-concentration essential oil will include 0.1 ml of essential oil per jar.

Interventions

Budesonide

The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.

Intervention Type: DRUG

High-Concentration Essential Oil

High-concentration essential oil will include 1 ml of essential oil per jar.

Intervention Type: BEHAVIORAL

Placebo

The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.

Intervention Type: DRUG

Low-Concentration Essential Oil

Low-concentration essential oil will include 0.1 ml of essential oil per jar.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Adult women and men.
• Positive laboratory finding for SARS-CoV-2 (e.g., real-time reverse-transcription polymerase chain reaction (rRT-PCR) assays to detect viral RNA).
• In convalescence from their COVID-19 illness.
• Subjective complaints of reduced olfaction after COVID-19 infection of greater than 3 months duration.
• Reduced olfaction ability as determined by a score of <35 (women) or <34 (men) on the University of Pennsylvania Smell Identification Test (UPSIT ).
• Ability to read, write, and understand English.

Exclusion Criteria

• History of olfaction disorder prior to COVID-19 infection.
• History of nasal cavity polyps.
• Dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease.
• History of cerebrospinal fluid leak.
• History of allergy to budesonide or other topical steroids.
• Pregnant or breast feeding or intend to become pregnant during the course of the trial.
• Current infection or history of one of the following infections: Tuberculosis (TB) lung infection, or Herpes infection of the eye.
• Baseline UPSIT score 5 or below, which suggests malingering.
• History of neurodegenerative disease (i.e. Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Jay F. Piccirillo, MD

Prof of Otolaryngology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Washington University

St Louis, Missouri, United States

Countries

United States

Other Identifiers

PA-18-334

Identifier Type: -

Identifier Source: org_study_id